ProCE Banner Activity

Myeloid Malignancies Clinical Advances Journal Club on Emerging Data for AML: Answers to Frequently Asked Questions

Clinical Thought

A commentary covering frequently asked questions from healthcare professionals related to emerging clinical data for patients with low-risk and high-risk AML.

Released: July 22, 2024

Expiration: July 21, 2025

Share

Faculty

Courtney DiNardo

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb

Bristol Myers Squibb

Disclosure

Primary Author

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Rigel, Servier, Schrodinger.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, CTI Biopharma, Daiichi Sankyo, Gilead, GlaxoSmithKline, Immunogen, Johnson & Johnson, Kite, Kura, Novartis, Qiagen, Rigel, Schrodinger, Sellas, Stemline, Sumitomo, Syndax.